GlassScriptPhysician profile
Lynley Taylor Ferrell
NPI 1750031084
$7,328.37
in general payments reported to CMS, 2019-2025
23 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $849 · 2023: $1,430 · 2024: $2,588 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,049 · Education: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,048.80 |
| Education | $430.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,685.49 | 2022-2025 | Tremfya |
| Abbvie INC. | $1,184.68 | 2022-2025 | |
| Ucb, INC. | $930.42 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $590.14 | 2023-2025 | Zoryve |
| Pfizer INC. | $485.87 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $453.04 | 2023-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $344.04 | 2023-2024 | Sotyktu |
| Incyte Corporation | $241.00 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $192.32 | 2022-2025 | |
| Galderma Laboratories, L.P. | $178.89 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $172.23 | 2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $170.92 | 2022-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Almirall LLC | $123.07 | 2022-2025 | Klisyri |
| Lilly USA, LLC | $110.61 | 2023-2025 | Taltz, Olumiant, Ebglyss |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $110.16 | 2022 | |
| Genzyme Corporation | $63.69 | 2022-2025 | |
| Organon LLC | $39.68 | 2025 | Vtama |
| Dermavant Sciences, INC. | $38.85 | 2023-2024 | Vtama |
| Merck Sharp & Dohme LLC | $31.51 | 2023 | Keytruda |
| Mayne Pharma Commercial LLC | $23.27 | 2025 | |
| Kerecis Limited | $19.67 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Verrica Pharmaceuticals INC. | $13.82 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynley Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.